OS Therapies (OSTX) Return on Capital Employed (2024 - 2026)
OS Therapies' (OSTX) quarterly Return on Capital Employed came in at 342.74% in Q1 2026, up 116618.0% YoY from N/an in Q1 2025, and down 53.82% on a QoQ basis from 742.12% in Q4 2025.
OS Therapies (OSTX) Return on Capital Employed (2024 - 2026) Analysis & Trends
OS Therapies (OSTX) has 3 years of Return on Capital Employed data on file, last reported at 342.74% in Q1 2026.
- Quarterly Return on Capital Employed rose 116618.0% year-over-year to 342.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 342.74% (up 116618.0% YoY) and the FY2025 annual result came in at 514.87%, up 4781.0% from the prior year.
- Return on Capital Employed declined to 342.74% in Q1 2026, from 742.12% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 783.85% in Q4 2024 to a low of 823.44% in Q1 2025.
- A 3-year average of 95.12% and a median of 15.37% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed slumped 90000 bps — and 2026, when it surged 116618 bps.
- Tracing OSTX's Return on Capital Employed over 3 years: stood at 783.85% in 2024, then decreased by 5 bps to 742.12% in 2025, then sank by 54 bps to 342.74% in 2026.
- The last three Return on Capital Employed figures came in at 342.74% (Q1 2026), 742.12% (Q4 2025), and 358.77% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | 312.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 342.74% |
| Dec 31, 2025 | 742.12% |
| Sep 30, 2025 | -358.77% |
| Jun 30, 2025 | -398.78% |
| Mar 31, 2025 | -823.44% |
| Dec 31, 2024 | 783.85% |
| Sep 30, 2024 | 541.23% |
| Jun 30, 2024 | 11.76% |
| Mar 31, 2024 | 15.37% |